ABD - İngilizce - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - ciclopirox 80 mg in 1 ml - (to understand fully the indication for this product, please read the entire indications and usage section of the labeling.) ciclopirox topical solution, 8% as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to trichophyton rubrum . the comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. - no studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. - ciclopirox topical solution, 8% should be used only under medical

Kanada - İngilizce - Health Canada

pharmascience inc - ciclopirox - solution - 8% - ciclopirox 8% - hydroxypyridones

Kanada - İngilizce - Health Canada

taro pharmaceuticals inc - ciclopirox - solution - 8% - ciclopirox 8% - hydroxypyridones

ABD - İngilizce - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - none. teratogenic effects: pregnancy category b there are no adequate or well-controlled studies in pregnant women. therefore, ciclopirox shampoo should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral embryofetal developmental studies were conducted in mice, rats, rabbits and monkeys. ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. no maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 77, 125, 80 and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits and monkeys, respectively (approximately 13, 42, 54 and 26 times the maximum recommended human dose based on body surface area comparisons, respectively). dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in peg 400. ciclopirox olamine was topically administered during the period of organogenesis. no maternal toxicity, embryotoxicity or teratogenicity were noted at the hig

ABD - İngilizce - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - (to understand fully the indication for this product, please read the entire indications and usage section of the labeling.) ciclopirox topical solution, 8% (nail lacquer) as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to tricho-phyto rubrum . the comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. the results of use of ciclopirox topical solution, 8% (nail lacquer) in treatment of onychomycosis of the toenail without lunula involvement were obtained from two double-blind, placebo-controlled studies conducted in the us. in these studies, patients with onchomycosis of the great toenails without lunula involvement were treated with ciclopirox topical solu

ABD - İngilizce - NLM (National Library of Medicine)

teligent pharma, inc. - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - none. teratogenic effects: pregnancy category b there are no adequate or well-controlled studies in pregnant women. therefore, ciclopirox shampoo should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral embryofetal developmental studies were conducted in mice, rats, rabbits and monkeys. ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. no maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 77, 125, 80 and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits and monkeys, respectively (approximately 13, 42, 54 and 26 times the maximum recommended human dose based on body surface area comparisons, respectively). dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in peg 400. ciclopirox olamine was topically administered during the period of organogenesis. no maternal toxicity, embryotoxicity or teratogenicity were noted at the hig

ABD - İngilizce - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - (to understand fully the indication for this product, please read the entire indications and usage section of the labeling.) ciclopirox topical solution, 8%, (nail lacquer), as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to trichophyton rubrum . the comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. - no studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. - ciclopirox topical solution, 8%, (nail lacquer), should be used

ABD - İngilizce - NLM (National Library of Medicine)

bryant ranch prepack - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - (to understand fully the indication for this product, please read the entire indications and usagesection of the labeling.) ciclopirox topical solution, 8% as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to trichophyton rubrum . the comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. - no studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. - ciclopirox topical solution, 8% should be used only under medical supervision as desc

ABD - İngilizce - NLM (National Library of Medicine)

bryant ranch prepack - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - superficial dermatophyte infections ciclopirox gel, 0.77% is indicated for the topical treatment of interdigital tinea pedis and tinea corporis due to trichophyton rubrum, trichophyton mentagrophytes, or epidermophyton floccosum . seborrheic dermatitis ciclopirox gel, 0.77% is indicated for the topical treatment of seborrheic dermatitis of the scalp. ciclopirox gel, 0.77% is contraindicated in individuals who have shown hypersensitivity to any of its components.

ABD - İngilizce - NLM (National Library of Medicine)

bryant ranch prepack - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - superficial dermatophyte infections ciclopirox gel, 0.77% is indicated for the topical treatment of interdigital tinea pedis and tinea corporis due to trichophyton rubrum, trichophyton mentagrophytes, or epidermophyton floccosum . seborrheic dermatitis ciclopirox gel, 0.77% is indicated for the topical treatment of seborrheic dermatitis of the scalp. ciclopirox gel, 0.77% is contraindicated in individuals who have shown hypersensitivity to any of its components.